KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Income from Continuing Operations (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Income from Continuing Operations for 18 consecutive years, with 92528000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations rose 37.03% year-over-year to 92528000.0; the TTM value through Mar 2026 reached 54203000.0, up 1922.5%, while the annual FY2025 figure was 207000.0, 103.04% down from the prior year.
  • Income from Continuing Operations hit 92528000.0 in Q1 2026 for Ionis Pharmaceuticals, down from 151786000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 356363000.0 in Q4 2024 and bottomed at 147410000.0 in Q3 2023.
  • Average Income from Continuing Operations over 5 years is 42512529.41, with a median of 85248000.0 recorded in 2023.
  • Year-over-year, Income from Continuing Operations plummeted 213.58% in 2023 and then surged 3661.85% in 2024.
  • Ionis Pharmaceuticals' Income from Continuing Operations stood at 52467000.0 in 2022, then soared by 80.93% to 10005000.0 in 2023, then soared by 3661.85% to 356363000.0 in 2024, then crashed by 57.41% to 151786000.0 in 2025, then plummeted by 160.96% to 92528000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 92528000.0, 151786000.0, and 128606000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.